Liu Guangkuo, Li Bingqing
Department of Gastroenterology, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China.
J Cancer Res Ther. 2019;15(2):278-285. doi: 10.4103/jcrt.JCRT_135_18.
Although many modalities can be used to prolong the remission of colorectal cancer (CRC), early diagnosis is essential to improve the therapeutic outcomes. The conventional ways of diagnosing and monitoring the progresses from adenoma to CRC are colonoscopy and fecal occult blood test (FOBT). However, colonoscopy is expensive and invasive; while the FOBT is not sensitive. miRNAs may be a new modality to monitor the transition from adenoma to CRC. We reviewed publications of miRNA profile differences from colorectal normal mucosa (NM) to adenoma, and to CRC and tried to find the roles of miRNA in these transitions. This review also highlighted the possibility of serum miRNAs as markers for monitoring these transitions. The miRNA profiles are different from normal colorectal mucosa to adenoma and to CRC. The miRNAs may have pro- or anti-CRC effects through oncogenes such as c-Met and KRAS. Others may interfere with the immune system. More interestingly, some miRNAs are continuously increased from NM to adenoma and to CRC; others, such as miRNA-30b, are consequently decreased. The literature shows that miRNAs are involved in the whole process of the colorectal carcinogenesis. The miRNAs may be the biomarkers in monitoring the transition from adenoma to CRC.
尽管可以采用多种方法来延长结直肠癌(CRC)的缓解期,但早期诊断对于改善治疗效果至关重要。从腺瘤到CRC的诊断和进展监测的传统方法是结肠镜检查和粪便潜血试验(FOBT)。然而,结肠镜检查费用高昂且具有侵入性;而FOBT则不敏感。微小RNA(miRNA)可能是监测从腺瘤到CRC转变的一种新方法。我们回顾了从结直肠正常黏膜(NM)到腺瘤再到CRC的miRNA谱差异的相关出版物,并试图找出miRNA在这些转变中的作用。本综述还强调了血清miRNA作为监测这些转变标志物的可能性。从正常结直肠黏膜到腺瘤再到CRC,miRNA谱是不同的。miRNA可能通过c-Met和KRAS等癌基因产生促CRC或抗CRC作用。其他miRNA可能会干扰免疫系统。更有趣的是,一些miRNA从NM到腺瘤再到CRC持续增加;而其他miRNA,如miRNA-30b,则相应减少。文献表明,miRNA参与了结直肠癌发生的全过程。miRNA可能是监测从腺瘤到CRC转变的生物标志物。